Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: A systematic review and meta-analysis

Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment

“…Although differences exist among studies, most studies have reported that serum GPC3 expression was significantly higher in HCC patients than in healthy controls and patients with liver cirrhosis or CH. Additionally, the results of several meta‐analyses have suggested that serum GPC3 is upregulated in HCC patients, which indicates the potential of using serum GPC3 level in HCC diagnosis . Thus, further studies using the same antibodies and detection methods in cohorts with similar etiologies are required to achieve clarity regarding the diagnostic suitability of serum GPC3.…”

“…Additionally, the results of several meta-analyses have suggested that serum GPC3 is upregulated in HCC patients, which indicates the potential of using serum GPC3 level in HCC diagnosis. [110][111][112] Thus, further studies using the same antibodies and detection methods in cohorts with similar etiologies are required to achieve clarity regarding the diagnostic suitability of serum GPC3.…”

Performance of different biomarkers for the management of hepatocellular carcinoma

“…Its levels increase considerably in patients with HCC, while GPC3 is not detected in healthy liver tissue, so it has been identified as an useful tumor marker for HCC diagnosis [27] . Thus, in a recently published meta-analysis, sensitivity and specificity observed were of 0.53 (95% CI: 0.49-0.57) and 0.77 (95% CI: 0.74-0.81), respectively, with an AUC of 0.82 [28] . In addition, it seems to have a higher sensitivity than AFP, with similar specificity [29] , whereas their combination notably increase both sensitivity and specificity (98.5% and 97.8%, respectively) [30] .…”

Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma

“…The level of circulating AFP is a routine marker for diagnosis of HCC. However, an elevated AFP level results in a higher false positive rate in patients with benign liver diseases, greatly hampering the differential diagnosis ( Figure 1) (24,25). Circulating GPC-3 increases in patients with HCC, which implies that GPC-3 may be very valuable in diagnosing HCC and monitoring its progression.…”

“…Clinical studies have reported that GPC-3 is specifically over-expressed in HCC and that it is a valuable marker for diagnosis of HCC and estimation of its prognosis (17,24). GPC-3 promotes the growth of HCC by stimulating canonical Wnt signaling.…”